David Planchard/oncostream.com
May 1, 2025, 16:11
David Planchard Highlights Promise and Access Challenges of HER2-TKIs for HER2-Mutant NSCLC
David Planchard, Thoracic Oncologist, Professor at University Paris Saclay and Head of Thoracic Cancer Group at Gustave Roussy, shared a post on LinkedIn about a paper he co-authored with colleagues published in NEJM.
“After ADCs, HER2-TKIs arrive…impressive clinical activity and tolerance! Things are moving fast, but access is still difficult in Europe outside a clinical trial…unfortunately for our HER2-mutant patients!”
Title: Zongertinib in Previously Treated HER2-Mutant Non-Small-Cell Lung Cancer
Authors: John Heymach, Gerrina Ruiter, Myung-Ju Ahn, Nicolas Girard, Egbert Smit, David Planchard, Yi-Long Wu, Byoung Chul Cho, Noboru Yamamoto, Joshua Sabari, Yanqiu Zhao, Hai-Yan Tu, Kiyotaka Yoh, Ernest Nadal, Behbood Sadrolhefazi, Maren Rohrbacher, Ute von Wangenheim, Sabina Eigenbrod-Giese, Jon Zugazagoitia.
You can read the Full Article on NEJM.
More posts featuring David Planchard.
ADCs
Behbood Sadrolhefazi
Byoung Chul Cho
cancer
David Planchard
Egbert Smit
Ernest Nadal
Gerrina Ruiter
Hai-Yan Tu
HER2-TKIs
John Heymach
Jon Zugazagoitia
Joshua Sabari
Kiyotaka Yoh
Lung cancer
Maren Rohrbacher
Myung-Ju Ahn
Nicolas Girard
Noboru Yamamoto
non small cell lung cancer
NSCLC
OncoDaily
Oncology
Sabina Eigenbrod-Giese
targeted therapy
Ute von Wangenheim
Yanqiu Zhao
Yi-Long Wu
Zongertinib
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
May 1, 2025, 15:20
May 1, 2025, 14:51
May 1, 2025, 14:30
May 1, 2025, 14:00
May 1, 2025, 13:26
May 1, 2025, 13:03